Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cipla
Accenture
Healthtrust
Boehringer Ingelheim
Mallinckrodt

Generated: July 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,529,882

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,529,882 protect, and when does it expire?

Patent 8,529,882 protects INCIVEK and is included in one NDA.

This patent has one hundred and five patent family members in thirty-six countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 8,529,882
Title:Peptidomimetic protease inhibitors
Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
Inventor(s): Babine; Robert Edward (Franklin, MA), Chen; Shu Hui (Carmel, IN), Collado; Ivan (Madrid, ES), Garcia-Paredes; Cristina (Madrid, ES), Glass; John Irvin (Indianapolis, IN), Jin; Ling (Carmel, IN), Lamar; Jason Eric (Indianapolis, IN), Parker, III; Raymond Samuel (Doylestown, PA), Snyder; Nancy June (Lizton, IN), Sun; Xicheng David (Superior, CO), Guo; Deqi (Carmel, IN), Yip; Yvonne Yee Mai (Indianapolis, IN), Wang; Q. May (Indianapolis, IN), Victor; Frantz (Indianapolis, IN), Tebbe; Mark Joseph (Hamburg, DE), Perni; Robert B. (Marlborough, MA), Farmer; Luc (Montreal, CA)
Assignee: Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:13/541,436
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,529,882
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,529,882

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vertex Pharms INCIVEK telaprevir TABLET;ORAL 201917-001 May 23, 2011 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF TREATING CHRONIC HEPATITIS C ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 8,529,882

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 030591 ➤ Try a Free Trial
Austria 431358 ➤ Try a Free Trial
Austria 483686 ➤ Try a Free Trial
Australia 2001288318 ➤ Try a Free Trial
Australia 8831801 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Julphar
Mallinckrodt
Deloitte
Citi
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.